Drug discovery strategies: technologies to accelerate translation from target to drug.
The development of new molecular therapeutics for cancer treatment is based on the identification of molecular abnormalities that drive the malignant process. The discovery of novel molecular targets is made quicker and more efficient by use of powerful high throughput technologies such as genome sequencing and gene expression microarrays. Similarly, the drug discovery process is being accelerated by a range of other valuable technologies. Using these approaches, we can expect to see a range of personalised molecular therapeutics becoming available for cancer treatment.
Workman
P
P
Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK. paul.workman@icr.ac.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015195:Drug Design; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005260:Female; D005544:Forecasting; D018390:Gene Targeting; D006801:Humans; D008297:Male; D018832:Molecular Chaperones; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D013678:Technology, Pharmaceutical / Q000592:standards / Q000639:trends*; D006113:United Kingdom
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D018832:Molecular Chaperones